NCT03844464View on ClinicalTrials.gov

Safety and Efficacy of Lorbrena

CompletedOBSERVATIONAL
Enrollment

1,290

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions
Non-small Cell Lung Cancer
Trial Locations (1)

151-8589

3-22-7, Yoyogi, Shibuya-ku, Tokyo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03844464 - Safety and Efficacy of Lorbrena | Biotech Hunter | Biotech Hunter